Montelukast and bronchial inflammation in asthma: A randomised, double-blind placebo-controlled trial

Respiratory Medicine

Volumn 103, Issue 7, 2009, Pages 995-1003

  Ramsay, C F ^a   Sullivan, P ^b   Gizycki, M ^b   Wang, D ^c   Swern, A S ^d   Barnes, N C ^a   Reiss, T F ^d   Jeffery, P K ^b  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Asthma; Eosinophils; Inflammation; Leukotrienes; Receptors

Indexed keywords

LEUKOTRIENE; LEUKOTRIENE RECEPTOR; MONTELUKAST; PLACEBO;

ADULT; ARTICLE; ASTHMA; BRONCHUS; BRONCHUS BIOPSY; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MAST CELL; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ACETATES; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; ASTHMA; CELL COUNT; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MAST CELLS; MIDDLE AGED; QUINOLINES; RESPIRATORY MUCOSA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67349197804     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.01.019     Document Type: Article

References (47)

1. Bousquet J., Jeffery P.K., Busse W.W., Johnson M., and Vignola A.M. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 161 (2000) 1720-1745
2. Jeffery P.K. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 164 (2001) S28-S38
3. Jeffery P.K., Godfrey R.W.A., Adelroth E., Nelson F., and Rogers A. Johansson S-A. Effects of treatment on airway inflammation and thickening of reticular collagen in asthma: a quantitative light and electron microscopic study. Am Rev Respir Dis 145 (1992) 890-899
4. Bentley A.M., Hamid Q., Robinson D.S., Schotman E., Meng Q., Assoufi B., Kay A.B., and Durham S.R. Prednisolone treatment in asthma: reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 153 (1996) 551-556
5. Ward C., Reid D.W., Orsida B.E., Feltis B., Ryan V.A., Johns D.P., and Walters E.H. Inter-relationships between airway inflammation, reticular basement membrane thickening and bronchial hyper-reactivity to methacholine in asthma; a systematic bronchoalveolar lavage and airway biopsy analysis. Clin Exp Allergy 35 (2005) 1565-1571
6. Sont J.K., Willems L.N., Bel E.H., van Krieken J.H., Vandenbroucke J.P., and Sterk P.J. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 159 (1999) 1043-1051
7. Laitinen L.A., Laitinen A., Haahtela T., Vilkka V., Spur B.W., and Lee T.H. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 341 (1993) 989-990
8. Currie G.P., and McLaughlin K. The expanding role of leukotriene receptor antagonists in chronic asthma. Ann Allergy Asthma Immunol 97 (2006) 731-741
9. Jeffery P.K. The roles of leukotrienes and the effects of leukotriene receptor antagonists in the inflammatory response and remodelling of allergic asthma. Clin Exp Allergy Rev 1 (2001) 148-153
10. Holgate S.T., Peters-Golden M., and Panettieri R.A. Henderson WR Jr. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 111 (2003) S18-S34
11. Wenzel S.E. The role of leukotrienes in asthma. Prostaglandins Leukot Essent Fatty Acids 69 (2003) 145-155
12. Henderson Jr. W.R., Lewis D.B., Albert R.K., Zhang Y., Lamm W.J., Chiang G.K., Jones F., Eriksen P., Tien Y.T., Jonas M., and Chi E.Y. The importance of leukotrienes in airway inflammation in a mouse model of asthma. J Exp Med 184 (1996) 1483-1494
13. Drazen J.M. Anti-leukotrienes as novel anti-inflammatory treatments in asthma. Adv Exp Med Biol 507 (2002) 217-221
14. Figueroa D.J., Breyer R.M., Defoe S.K., Kargman S., Daugherty B.L., Waldburger K., Liu Q., Clements M., Zeng Z., O'Neill G.P., Jones T.R., Lynch K.R., Austin C.P., and Evans J.F. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Resp Crit Care Med 163 (2001) 226-233
15. Lynch K.R., O'Neill G.P., Liu Q., Im D.S., Sawyer N., Metters K.M., Coulombe N., Abramovitz M., Figueroa D.J., Zeng Z., Connolly B.M., Bai C., Austin C.P., Chateauneuf A., Stocco R., Greig G.M., Kargman S., Hooks S.B., Hosfield E., Williams D.L.J., Ford-Hutchinson A.W., Caskey C.T., and Evans J.F. Nature 399 (1999) 789-793
16. Zhu J., Qiu Y.S., Figueroa D.J., Bandi V., Galczenski H., Hamada K., Guntupalli K.K., Evans J.F., and Jeffery P.K. Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa. Am J Respir Cell Mol Biol 33 (2005) 531-540
17. Reiss T.F., Chervinsky P., Dockhorn R.J., Shingo S., Seidenberg B., and Edwards T.B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 158 (1998) 1213-1220
18. Knorr B., Matz J., Bernstein J.A., Nguyen H., Seidenberg B.C., Reiss T.F., and Becker A. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 279 (1998) 1181-1186
19. Wenzel S.E., Trudeau J.B., Kaminsky D.A., Cohn J., Martin R.J., and Westcott J.Y. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 152 (1995) 897-905
20. Calhoun W.J., Lavins B.J., Minkwitz M.C., Evans R., Gleich G.J., and Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 157 (1998) 1381-1389
21. Pizzichini E., Leff J.A., Reiss T.F., Hendeles L., Boulet L.-P., Wei L.X., Efthimiadis A., Zhang J., and Hargreave F.E. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 14 (1999) 12-18
22. Laviolette M., Malmstrom K., Lu S., Chervinsky P., Pujet J.C., Peszek I., Zhang J., and Reiss T.F. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 160 (1999) 1862-1868
23. Krawiec M.E., and Wenzel S.E. Leukotriene inhibitors and non-steroidal therapies in the treatment of asthma. Expert Opin Pharmacother 2 (2001) 47-65
24. Volovitz B., Tabachnik E., Nussinovitch M., Shtaif B., Blau H., Gil-Ad I., Weizman A., and Varsano I. Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma. J Allergy Clin Immunol 104 (1999) 1162-1167
25. Nakamura Y., Hoshino M., Sim J.J., Ishii K., Hosaka K., and Sakamoto T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 53 (1998) 835-841
26. Sullivan P., Stephens D., Ansari T., Costello J., and Jeffery P. Variation in the measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies. Eur Respir J 12 (1998) 811-815
27. Lambert D. Zero-inflated Poisson regression, with an application to defects in manufacturing. Technometrics 34 (1992) 1-14
28. Böhning D., Dietz E., Schlattmann P., Mendonca L., and Kirchner U. The zero-inflated Poisson model and the decayed, missing and filled teeth index in dental epidemiology. J R Stat Soc Ser A 162 (1999) 195-209
29. Dietz E., and Böhning D. On estimation of the Poisson parameter in zero-modified Poisson models. Computl Stat Data Anal 34 (2000) 441-459
30. Trigg C.J., Manolitsas N.D., Wang J., Calderón M.A., McAulay A., Jordan S.E., Herdman M.J., Jhalli N., Duddle J.M., Hamilton S.A., et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 150 (1994) 17-22
31. Manolitsas N.D., Wang J., Devalia J.L., Trigg C.J., McAulay A.E., and Davies R.J. Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. Am J Respir Crit Care Med 151 (1995) 1925-1930
32. Biernacki W.A., Kharitonov S.A., Biernacka H.M., and Barnes P.J. Effect of montelukast on exhaled leukotrienes and quality of life in asthmatic patients. Chest 128 (2005) 1958-1963
33. Diamant Z., Grootendorst D.C., Veselic-Charvat M., Timmers M., de Smet M., Leff J.A., Seidenberg B., Zwinderman A.H., Peszek I., and Sterk P. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 29 (1999) 1-3
34. Panettieri R.A., Tan E.M., Ciocca V., Luttmann M.A., Leonard T.B., and Hay D.W. Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 19 (1998) 453-461
35. Parameswaran K., Cox G., Radford K., Janssen L.J., and Sehmi R. O'Byrne PM. Cysteinyl leukotrienes promote human airway smooth muscle migration. Am J Respir Crit Care Med 166 (2002) 738-742
36. Gizycki M.J., Adelroth E., Rogers A.V., O'Byrne P.M., and Jeffery P.K. Myofibroblast involvement in the allergen-induced late response in mild atopic asthma. Am J Respir Cell Mol Biol 16 (1997) 664-673
37. Kelly M.M., Chakir J., Vethanayagam D., Boulet L.P., Laviolette M., Gauldie J., and O'Byrne P.M. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest 130 (2006) 741-753
38. Overbeek S.E., O'Sullivan S., Leman K., Mulder P.G.H., Hoogsteden H.C., and Prins J.-B. Effect of montelukast compared with inhaled fluticasone on airway inflammation. Clin Exp Allergy 34 (2004) 1388-1394
39. Henderson Jr. W.R., Chiang G.K., Tien Y.T., and Chi E.Y. Reversal of allergen-induced airway remodeling by cysLT1 receptor blockade. Am J Respir Crit Care Med 173 (2006) 718-728
40. Wenzel S.E., Schwartz L.B., Langmack E.L., Halliday J.L., Trudeau J.B., Gibbs R.L., and Chu H.W. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160 (1999) 1001-1008
41. Berry M., Morgan A., Shaw D.E., Parker D., Green R., Brightling C., Bradding P., Wardlaw A.J., and Pavord I.D. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 62 (2007) 1043-1049
42. Richmond I., Booth H., Ward C., and Walters E.H. Intrasubject variability in the airway inflammation in biopsies in mild to moderate stable asthma. Am J Respir Crit Care Med 153 (1996) 899-903
43. Bentley A.M., Menz G., Storz C., Robinson D.S., Bradley B., Jeffery P.K., Durham S.R., and Kay A.B. Identification of T-lymphocytes, macrophages and activated eosinophils in the bronchial mucosa in intrinsic asthma: relationship to symptoms and bronchial responsiveness. Am Rev Respir Dis 146 (1992) 500-506
44. Gamble E., Qiu Y., Wang D., Zhu J., Vignola A.M., Kroegel C., Morell F., Hansel T.T., Pavord I.D., Rabe K.F., Barnes N.C., and Jeffery P.K. Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. Eur Respir J 27 (2006) 293-299
45. Gamble E., Burns W., Zhu J., Ansari T., De Rose V., Kips J., Barnes N.C., and Jeffery P.K. Variation of CD8+ T-lymphocytes around the bronchial internal perimeter in chronic bronchitis. Eur Respir J 22 (2003) 992-995
46. O'Byrne P.M. The demise of anti-IL-5 for asthma or not. Am J Respir Crit Care Med 176 (2007) 1059-1060
47. Jeffery P.K., Wenzel S.E., and Holgate S. Methods for the assessment of endobronchial biopsies in clinical research. Am J Respir Crit Care Med 168 Suppl. 6P2 (2003) S1-17